Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 20/20 | 0.76 |
| ▸ | LATS2 | Q9NRM7 | 10/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20547980 | 0.86 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL26177194 | 0.76 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL29474436 | 0.75 | STK17B (0.54) | LATS1LATS2 | |
| SCHEMBL2722686 | 0.75 | STK17B (0.54) | LATS1LATS2 | |
| SCHEMBL29893686 | 0.75 | LATS1 (0.53) | LATS1LATS2 | |
| SCHEMBL20574556 | 0.74 | LATS1 (0.71) | LATS1LATS2 | |
| SCHEMBL26177187 | 0.73 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL19924283 | 0.73 | LATS1 (0.43) | LATS1LATS2 | |
| SCHEMBL19924282 | 0.73 | LATS1 (0.43) | LATS1LATS2 | |
| SCHEMBL20547781 | 0.72 | LATS1 (1.00) | LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | LATS1 1/4885LATS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.